Last edition
News about "bispecific Antibody-Drug Conjugate"
Akeso Initiates Phase 2 Trial of TROP2/Nectin-4 Bispecific ADC in Advanced Breast Cancer
Akeso has dosed the first patient in a Phase 2 study of AK146D1 combined with ivonescimab, advancing its next-generation “IO2.0 + ADC2.0” approach for advanced breast cancer.
Bispecific Antibody-Drug Conjugate | 10/08/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members